Moderna, Inc. Common Stock (MRNA)

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)

Market region: US

Address: 325 Binney Street, Cambridge, MA, 02142

Market capitalization

88.52 billion USD (88,518,581,309 USD)

Listing date

12/07/2018

Weighted shares outstanding

399,235,889

Share class shares outstanding

399,235,889

https://www.modernatx.com